MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

Table 3

Frequency of application of multivariable regression models, based on study features, of the observational studies assessing the value of microRNAs as potential biomarkers for coronary artery disease and acute coronary syndrome.

Variable	Median (1st quartile; 3rd quartile)	Category		Model assumption	Interaction analysis	Sensitivity analysis	Crude and adjusted effect estimate	More than one adjusted model specified	Reporting at least > 2 items
Articles	—		56	29 (52%)	32 (57%)	30 (54%)	14 (25%)	19 (34%)	34 (61%)
		95% CI		39–64%	44–69%	41–66%	15–38%	23–47%	48–72%
Publication year	2013 (2012; 2014)
		2010-2011	12	7 (58%)	6 (50%)	7 (58%)	0 (0%)	3 (25%)	3 (25%)
		2012-2013	17	7 (41%)	10 (59%)	11 (65%)	5 (29%)	6 (35%)	6 (35%)
		2014-2015	25	13 (52%)	15 (60%)	11 (44%)	8 (32%)	9 (36%)	10 (40%)
		2016	2	2 (100%)	1 (50%)	1 (50%)	1 (50%)	1 (50%)	1 (50%)
Sample size	115 (58; 312)
		<100	30	13 (43%)	14 (47%)	12 (40%)	1 (3%)	4 (13%)	4 (13%)
		101–500	19	10 (53%)	12 (63%)	12 (63%)	7 (37%)	8 (42%)	9 (47%)
		>501	7	6 (86%)	6 (86%)	6 (86%)	6 (86%)	7 (100%)	7 (100%)
Design	—
		Cross-Sectional	11	7 (64%)	5 (45%)	8 (73%)	3 (27%)	5 (45%)	5 (45%)
		Cohort	36	17 (47%)	21 (58%)	17 (47%)	8 (22%)	10 (28%)	11 (31%)
		Case-Studies	9	5 (56%)	6 (67%)	5 (56%)	3 (33%)	4 (44%)	4 (44%)
Journal impact factor	3.4 (1.8; 5.8)
		<3	27	12 (44%)	8 (30%)	10 (37%)	4 (15%)	5 (18%)	5 (18%)
		3–6	16	8 (50%)	13 (81%)	13 (81%)	4 (35%)	7 (44%)	8 (50%)
		>6.01	13	9 (69%)	11 (85%)	7 (54%)	6 (46%)	7 (54%)	7 (54%)
Yearly Scopus citations	8 (3; 16)
		<7	24	11 (46%)	12 (50%)	10 (42%)	6 (25%)	5 (21%)	6 (25%)
		7–16	18	9 (50%)	11 (61%)	10 (56%)	5 (28%)	7 (39%)	7 (39%)
		>16.1	14	9 (64%)	9 (64%)	10 (54%)	3 (21%)	7 (50%)	7 (50%)